Messenger ribonucleic acid (mRNA) Synthesis Raw Materials Global Market Report 2024

The mrna synthesis raw materials market size has grown steadily in recent years. It will grow from $2.94 billion in 2023 to $3.02 billion in 2024 at a compound annual growth rate (CAGR) of 2.8%. The growth observed in the historical period can be attributed to several factors, including notable advancements in biomedical research, a heightened interest in vaccines and therapeutic developments, increased demand for personalized medicine, focus on outbreak preparedness and response measures, and the overall expansion of the biotechnology industry.

The mrna synthesis raw materials market size is expected to see steady growth in the next few years. It will grow to $3.39 billion in 2028 at a compound annual growth rate (CAGR) of 2.9%. The projected growth during the forecasted period is driven by enhancements in supply chain efficiency, increased commercial activities, expanded market reach, amplified investments in biotechnology and pharmaceuticals, bolstered regulatory backing and approvals, and broader therapeutic advancements. Key trends anticipated in this period encompass the rise of new industry participants, heightened emphasis on quality control and standardization, focus on intellectual property rights and licensing, pursuit of global accessibility and fairness, and a notable shift towards environmentally sustainable and scalable manufacturing practices.

The mRNA synthesis raw materials market is anticipated to witness growth, driven by the increasing incidence of cancer and chronic disorders. Cancer, characterized by the uncontrolled development of aberrant cells that can spread to other parts of the body, and chronic disorders, persisting for a year or longer and requiring ongoing medical attention, create a demand for mRNA synthesis raw materials. These materials play a crucial role in drug discovery, vaccine development, and the manufacturing of RNA-based therapeutics, offering advantages such as improved immunogenicity, higher efficiency, and a short production time. For example, in April 2022, the American Cancer Society reported 1.92 million new cancer cases in the U.S., indicating a rise from 1.89 million cases in 2021. Additionally, the National Council on Aging's statistics revealed that about 80% of individuals aged 65 and older in the United States will experience at least one chronic ailment, with 68% having two or more. Consequently, the growing incidence of cancer and chronic disorders is a significant driver for the mRNA synthesis raw materials market.

Government initiatives supporting mRNA technology are poised to drive the growth of the mRNA synthesis raw materials market. These initiatives encompass coordinated efforts, programs, policies, and financial backing by governmental entities to promote research, development, and application of Messenger RNA (mRNA) technology. Such government support creates a conducive environment for the mRNA synthesis raw materials market by providing funding, infrastructure, regulatory backing, and opportunities for global collaboration. As of February 2023, The BMJ reported that the US government has invested $31.9 billion in mRNA COVID-19 vaccines post-pandemic. Despite financial support, it is noteworthy that the costs for mRNA vaccines from companies such as Pfizer-BioNTech and Moderna have increased over time, reflecting the evolving landscape of vaccine pricing. Specifically, the pricing per dose for Pfizer-BioNTech's vaccine increased from $19.50 in 2020 to $30.48 for the bivalent booster in 2022, while Moderna's costs rose from $15.25 per dose in 2020 to $26.36 in 2022. Hence, government initiatives for mRNA technology play a pivotal role in propelling the growth of the mRNA synthesis raw materials market.

The mRNA synthesis raw materials market is witnessing a notable trend with the increasing emphasis on product innovations. Key players in this market are strategically focusing on the development of innovative products to enhance their market positioning. An illustrative example is Thermo Fisher Scientific, a prominent US-based company specializing in instrumentation, reagents, consumables, and software services. In September 2022, the company introduced Dynabeads Solutions, a revolutionary bead designed for scaling GMP-grade synthesis and purification of mRNA for vaccine development. The Dynabeads Streptavidin for In Vitro Transcription facilitates solid-phase IVT of cell-free mRNA, enabling the reuse of the DNA template up to six times. This innovation not only streamlines the plasmid creation process but also enhances mRNA yield on scales ranging from grams to grams. Consequently, it supports the development of a streamlined pipeline, enabling mRNA firms to expedite the transition from development to commercialization.

Major players in the mRNA synthesis raw materials market are actively engaged in the development of raw materials to boost their profitability and market share. Innovations in raw materials and their quality play a pivotal role in enhancing the efficiency, yield, and safety of mRNA synthesis processes, thereby influencing the overall success of applications in biotechnology and medicine. As an instance, in September 2022, TriLink BioTechnologies, a prominent US-based biotechnology company, introduced N1-Methyl-Pseudouridine-5’-Triphosphate, a crucial raw material in the production of various mRNA drugs. This innovative product facilitates accelerated drug discovery, meeting the rising demand for N1-methyl-pseudouridine modified mRNA. TriLink BioTechnologies' commitment to providing unmatched analytical capabilities and GMP-grade offerings underscores its dedication to advancing groundbreaking mRNA-based therapies globally.

In January 2022, Maravai LifeSciences, a United States-centered life sciences enterprise, completed the acquisition of MyChem for $240 million. This strategic acquisition is geared towards enhancing Maravai LifeSciences' array of nucleic acid production offerings and expediting its research and development capacities. MyChem, a company situated in the US, specializes in the manufacturing of nucleotides, making this acquisition a significant move for Maravai's expansion within this sector.

Major companies operating in the messenger ribonucleic acid (mrna) synthesis raw materials market report are Pfizer Inc., F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Moderna Inc, Agilent Technologies Inc., Lonza Group Ltd., Eurofins Scientific, Bio-Rad Laboratories Inc., Qiagen N.V., Maravai LifeSciences, Takara Bio Inc., GenScript Biotech Corporation, Promega Corporation, Abcam plc, BioLegend Inc., Integrated DNA Technologies Inc., Sino Biological Inc., CureVac N.V., LGC Biosearch Technologies, Enzo Biochem Inc, Merck KGaA, GeneCopoeia Inc., Bio-Synthesis Inc., BOC Sciences Inc, Bio Basic Inc., OriGene Technologies Inc., BioCat GmbH, Creative Biogene, Jena Bioscience GmbH, ATDBio Ltd.

North America was the largest region in the mRNA synthesis raw materials market in 2023. The regions covered in the messenger ribonucleic acid (mrna) synthesis raw materials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the messenger ribonucleic acid (mrna) synthesis raw materials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Key components of mRNA synthesis raw materials encompass capping agents, nucleotides, plasmid DNA, among others. Capping agents, for instance, are amphiphilic molecules featuring a polar head group and a non-polar hydrocarbon tail. These agents are utilized in introducing modified cap structures to mRNA molecules during synthesis, imparting stability and protection to the mRNA. This enhances translation efficiency and fortifies the mRNA against degradation. These materials find diverse applications in therapeutics and vaccine production and are commonly employed by biotechnology firms, pharmaceutical companies, research institutions, and similar entities.

The mRNA synthesis raw materials market research report is one of a series of new reports that provides mRNA synthesis raw materials market statistics, including mRNA synthesis raw materials industry global market size, regional shares, competitors with mRNA synthesis raw materials market share, detailed mRNA synthesis raw materials market segments, market trends, and opportunities, and any further data you may need to thrive in the mRNA synthesis raw materials industry. This mRNA synthesis raw materials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The mRNA synthesis raw materials market consists of sales of modified ribonucleoside triphosphates, polynucleotide tails, ribonucleoside diphosphate (NDPs), ribonucleoside monophosphate (NMPs), and ribonucleoside triphosphate (NTTs). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.